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Summary 1
1. Summary
The incidence of cardiovascular diseases including cardiac hypertrophy and failure in 
pre-menopausal women is lower compared to age-matched men but the risk of heart 
disease increases substantially after the onset of menopause. It has been postulated 
that female sex hormones play an important role in cardiovascular health in pre-
menopausal women. In animal studies including spontaneously hypertensive (SHR) 
rats, the development of cardiac hypertrophy is attenuated by 17β-estradiol treatment.
Cardiac energy metabolism is crucial for normal function of the heart. In cardiac 
hypertrophy and heart failure, the myocardium undergoes a metabolic shift from fatty 
acid as primary cardiac energy source to glucose, which re-introduces the fetal type of 
metabolism that representing the glucose as a major source of energy. Many studies 
have reported that the disruption of the balance between glucose and fatty acid 
metabolism plays an important role in cardiac pathologies including hypertrophy, 
heart failure, diabetes, dilative cardiomyopathy and myocardial infarction. Glucose 
enters cardiomyocytes via GLUT1 and GLUT4 glucose transporters and GLUT4 is 
the major glucose transporter which is insulin-dependent. Cardiac-selective GLUT4
deficiency leads to cardiac hypertrophy. This shows that the decrease in cardiac 
glucose uptake may play a direct role in the pathogenesis of cardiac hypertrophy. 
Estrogens modulate glucose homeostasis in the liver and the skeletal muscle. But it is 
not known whether estrogens affect also cardiac glucose uptake which could provide
another mechanism to explain the prevention of cardiac hypertrophy by female sex 
hormones. In the present study, SHR Rats were ovariectomized (OVX), not 
ovariectomized (sham) or ovariectomized and treated with subcutaneous 17β-
estradiol. After 6 weeks of treatment, body weight, the serum levels of estrogen, 
insulin, intra-peritoneal glucose tolerance test (IP-GTT), myocardial glucose uptake 
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by FDG-PET (2-(18F)-fluoro-deoxyglucose (18FDG) and Positron Emission 
Tomography), cardiac glucose transporter expression and localization and cardiac 
hexokinase activity were analyzed. As results of this study, PET analysis of female 
SHR revealed decreased cardiac glucose uptake in OVX animals compared to intact
that was normalized by estrogen supplementation. Interestingly, there was no change 
in global glucose tolerance among the treatment groups. Serum insulin levels and 
cardiac hexokinase activity were elevated by E2 substitution. The protein content of 
cardiac glucose transporters GLUT-4 and GLUT-1, and their translocation as 
determined by fractionation studies and immuno-staining did not show any significant
change by ovariectomy and estrogen replacement. Also levels of insulin receptor 
substrate-1 (IRS-1) and its tyrosine phosphorylation, which is required for activation 
and translocation of GLUT4, was un-affected in all groups of SHR. Cardiac gene 
expression analysis in SHR heart showed that ei4Ebp1 and Frap1 genes which are 
involved in the mTOR signaling pathway, were differentially expressed upon estrogen 
treatment. These genes are known to be activated in presence of glucose in the heart. 
As a conclusion of this study, reduced myocardial FDG uptake in ovariectomized 
spontaneously hypertensive rat is normalized by 17β-estradiol treatment. Increased 
myocardial hexokinase appears as a potential mechanism to explain increased 
myocardial glucose uptake by 17β-estradiol.  Increased cardiac glucose uptake in 
response to 17β-estradiol in ovariectomized SHR may provide a novel mechanism to 
explain the reduction of cardiac hypertrophy in E2 treated SHR. Therefore, 17β-
estradiol improves cardiac glucose utilization in ovariectomized SHR which may give 
rise to possible mechanism for its protective effects against cardiac hypertrophy. 
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1(a). Zusamanfassung
Erkrankungen des kardiovaskulären Systems, wie beispielsweise Herzhypertrophie 
oder Herzinsuffizienz treten bei Frauen vor der Menopause im Vergleich zu 
gleichaltrigen Männern seltener auf. Das Risiko für eine solche kardiovaskuläre 
Erkrankung steigt jedoch drastisch mit dem Beginn der Menopause an. Aus diesem 
Grund wird angenommen, dass weibliche Geschlechtshormone kardioprotektive 
Wirkungen besitzen. Tierstudien an spontan hypertensiven Ratten (SHR) haben 
belegt, dass eine Herzhypertrophie durch die Behandlung der Tiere mit 17β-Estradiol 
abgemildert werden kann. Entscheidend für die Funktion des Myokards ist sein 
Energiemetabolimus, der sich im Verlauf einer Hypertrophie oder Herzinsuffizienz 
vom primären Fettsäurestoffwechsel auf Glucosemetabolismus umschaltet. Diese 
Situation entspricht der des fetalen Herzens. Viele Studien haben belegt, dass eine 
Störung der Balance zwischen Glucose- und Fettsäurestoffwechsel oftmals ein erstes 
Anzeichen für einen pathologischen Zustand des Herzens, wie z.B. Hypertrophie, 
Herzinsuffizienz, Diabetes, dilative Kardiomyopathie und Myokardinfarkt ist.  Im 
gesunden Herzen gelangt Glucose über die zwei Glucosetransporter GLUT1 und 
GLUT4 in die Zellen des Myokards, wobei der insulinabhängige Glut4-Transporter 
der Hauptglucosetransporter ist. Eine GLUT4-Defizienz führt daher ebenfalls zu einer 
Herzhypertrophie was wiederum zeigt, dass eine verminderte Glucoseaufnahme im 
direkten Zusammenhang mit pathologischen Zuständen des Herzens steht. Bisherige 
Studien haben gezeigt, dass Östrogen an der Glucosehomöostase in Leber und 
Skelettmuskeln beteiligt ist. Jedoch ist wenig darüber bekannt, ob Östrogen ebenfalls 
in die kardiale Glucosehomöostase eingreift und inwiefern die kardioprotektive 
Wirkung des Östrogens in diesem Zusammenhang steht.In der vorliegenden Arbeit 
wurden weibliche SH-Ratten ovariektomiert (OVX), nicht ovariektomiert (sham) oder 
ovariektomiert und zusätzlich subkutan mit 17β-Estradiol behandelt. Nach einer 
Behandlungszeit von 6 Wochen wurden dann das Körpergewicht, die Serumspiegel 
von Östrogen, Insulin und IPGTT bestimmt, und die Glucoseaufnahme des Myokards 
mittels FDG-PET analysiert. Zusätzlich wurden Expression und zelluläre Lokalisation 
der kardialen Glucosetransporter sowie die kardiale Hexokinaseaktivität untersucht. 
Es konnte gezeigt werden, dass sich eine verminderte Glucoseaufnahme des Herzens 
bei ovariektomierten Tieren durch Östrogen-Supplementation normalisieren lässt. 
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Eine Abweichung bezüglich der Glucosetoleranz der einzelnen Gruppen konnte nicht 
beobachtet werden. Jedoch konnte ein erhöhter Insulinspiegel des Serums und eine 
erhöhte kardiale Aktivität des Enzyms Hexokinase durch die Behandlung mit 
Östrogen bei den ovariektomierten Tieren beschrieben werden. Durch 
Fraktionierungen und immunhistologische Untersuchungen konnte kein signifikanter 
Unterschied in Bezug auf die Menge sowie die Translokation der Glucosetransporter 
GLUT1 und GLUT4 im Myokard zwischen den einzelnen Behandlungen der Tiere 
beschrieben werden. Ferner konnte zwischen den einzelnen Tiergruppen auch kein 
Unterschied zwischen dem Insulin Rezeptor Substrat-1 (IRS-1) und seiner Tyrosin-
phosphorylierten Form festgestellt werden, die für die Aktivierung und Translokation 
des GLUT4 benötigt werden. Analysen der Genexpression in den Herzen der SH-
Ratten konnten allerdings zeigen, dass die Gene ei4Ebp1 und  Frap1, die im mTOR 
Signalweg involviert sind, bei den Östrogen-supplementierten Tieren ein 
abweichendes Expressionsmuster aufweisen. Über diese Gene ist bekannt, dass sie in 
der Gegenwart von Glucose im Herzen aktiviert werden und bei der Entstehung einer 
Herzhypertrophie mitwirken. Basierend auf den PET-Analysen und der 
Hexokinaseaktivität lässt sich als Resultat dieser Arbeit aussagen, dass Östrogen die 
kardiale Glucoseaufnahme in SH-Ratten fördert. Diese Ergebnisse könnten einen 
Hinweis auf einen noch unbekannten Mechanismus geben, um die protektive 
Wirkung des Östrogens im Hinblick auf die Herzhypertrophie zu erklären. 
Hinsichtlich der Tatsache, dass keine Veränderungen in der Translokation der 
GLUT4-Transporter in der Plasmamembran bei den einzelnen Behandlungen der 
Tiere zu verzeichnen sind, jedoch Veränderungen der Glucoseaufnahme durch die 
PET-Analysen dargestellt werden konnten, besteht jedoch noch Erklärungsbedarf. Es 
liegen diverse Studien vor, die diesen Unterschied damit erklären könnten, dass der 
GLUT4-Transporter in einer inaktiven Form in der Plasmamembran vorliegt bis die 
Glucoseaufnahme durch den GLUT4-Transporter mittels der Insulin 
Signaltransduktionskaskade reguliert wird.
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2. Introduction
Cardiac hypertrophy, clinically defined as an increase in ventricular mass is an 
independent risk factor for cardiovascular disease which is a major cause of morbidity 
and mortality (Levy, Garrison et al. 1990). Women have a lesser prevalence for left 
ventricular hypertrophy (LVH) than men but heart disease increases in 
postmenopausal women compared to age matched males (Agabiti-Rosei and Muiesan 
2002). In animal studies, pressure over-load hypertrophy in ovariectomized mice was 
reduced by 17β-estradiol substitution (van Eickels, Grohe et al. 2001). Cardiac 
hypertrophy is associated with altered cardiac energy demand which promotes a shift 
in energy substrate utilization from fatty acid to glucose. Matching of energy 
metabolism to cardiac demand is very important for heart function and fine tuning of
the balance between fatty acid and glucose utilization leveled under physiological 
condition. The healthy adult heart makes mainly use of long chain fatty acids for its 
energy requirements (65–90%); the remaining energy is provided by glucose and 
lactate oxidation. Interruption of the balance between fatty acid and glucose 
metabolism is frequently noticed in cardiac pathologies (Carvajal and Moreno-
Sanchez 2003; Davidoff 2006). Myocardium subjected to a metabolic switch from 
fatty acid to glucose, reintroduces the fetal substrate metabolic design (Bishop and 
Altschuld 1970; Taegtmeyer and Overturf 1988; Yonekura, Brill et al. 1985).  
Changes in energy metabolism decrease cardiac ATP levels and cause a shift in 
contractile protein isoforms expression (α & β MHC). The re-entry of fetal 
metabolism and metabolic adaptation toward glucose utilization occurs early not
before any change in cardiac mass in hypertensive animals (Taegtmeyer and Overturf 
1988). This advocates that the change in metabolic substrate utilization to cardiac 
overload precedes cardiac hypertrophy. The foetal switch appears to be opposite to 
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systemic insulin resistance (Kemppainen, Tsuchida et al. 2003) and decreased 
myocardial FDG uptake in failing human heart (Razeghi, Young et al. 2001). The 
occurrence of hypertension, insulin resistance and type II diabetes is increased in 
postmenopausal women which have been shown to have decreased myocardial 
glucose uptake. While the development of hypertrophy and cardiac failure is 
characterized by a gradual decrease in fatty acid utilization, compensated by increased 
glucose utilization, the diabetic heart suffers from impaired glucose uptake, and relies 
almost completely on fatty acid oxidation. Estrogen is known to maintain glucose 
metabolism in liver and skeletal muscle. Estrogen controls insulin secretion and 
release and also expression of glucose transporters in non-cardiac tissues.  Genetic 
alterations in cardiac glucose uptake also adversely affect cardiac function, for 
instance the disruption of glucose transport by deletion of cardiac specific insulin 
responsive GLUT4, which is a major glucose transporter, leads to cardiac 
hypertrophy, myocardial insulin resistance and compensatory expression of the basal 
glucose transporter GLUT1. Therefore, the present study is mainly to determine 
whether alteration in cardiac glucose uptake and utilization might contribute to the 
role of estrogen in preventing development of cardiac hypertrophy in female 
spontaneously hypertensive rats. 
2.1. Estrogen and Estrogen Receptors
Estrogens are steroid hormones produced primarily in ovary, testis, and adrenal 
cortex. Estrogens regulate the oestrous cycle, promote the development of secondary 
sexual characters in females and are important for female and male reproduction. 
Estrogens are derived from cholesterol (fig.1.). There are three naturally occurring 
estrogens namely estradiol, which is the main ovarian estrogen and has greater 
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Fig.1. Illustration of Estrogen Biosynthetic Pathway. 
Estrogen mediates its effects through estrogen receptors (ER) to activate specific 
target genes. There are two different isoforms of ER namely ER- and ER- (fig.2).  
ER- homologues to ER- in the DNA binding domain (97% amino acid identity) 
and in ligand binding domain (55% amino acid identity) (Enmark and Gustafsson 
1999; Kuiper, Enmark et al. 1996). The structural features of the ER’s share
homologies with other member of nuclear receptor super family in having 5 different 
domains A/B, C, D, E and F. A/B participates in activation of transcription of target
genes, C is the DNA binding domain. The D domain functions as hinge between DNA 
binding domain and E-domain and the E domain, which is important for ligand 
binding, receptor dimerization and transcription activation. The F domain is not 
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present in all nuclear receptor family members and its role is not yet revealed. Both
ERs have different ligand binding properties.
    
Fig.2. Illustration of the structure of the Estrogen Receptor(ER). 
SERMs (Selective Estrogen Receptor Modulators) are compounds which function as 
ER agonists in some tissues and block estrogen action in other tissues (Dutertre and 
Smith 2000; Kuiper, Enmark et al. 1996). Distribution of estrogen receptors may also
account for tissue specific effect of estrogen (Couse and Korach 1999; Kuiper, 
Carlsson et al. 1997)
2.2. Mechanism of Estrogen Signalling
The classical confer actions of estrogen are genomic effects which arise from estrogen 
receptor by interaction with DNA and activate or repress the specific set of gene 
DNA binding-ligand binding
Hsp 60 binding
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Nuclear Localizationn
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expression. Estrogen confers also non-genomic effects which account for 
transcriptional activation or repression of target genes at apace manner (fig.3).
2.2.1. Genomic Effects of Estrogen
Estrogen diffuses through the plasma membrane and the nuclear membrane of the
cell. Intracellular estrogen binds to estrogen receptors which are present in a complex 
with proteins like heat shock proteins. The dissociation of estrogen receptor from heat 
shock proteins promotes dimerization of receptor protein (Auricchio, Migliaccio et al.
1990; Landers and Spelsberg 1992; Pratt and Toft 1997). The activated ER bind 
directly to Estrogen Response Elements (ERE) as homodimer or heterodimers and 
facilitates the transcription of target mRNA synthesis (Klein-Hitpass, Schorpp et al.
1986; Nilsson and Gustafsson 2002; Peale, Ludwig et al. 1988) or indirectly through 
transcription factors (Nilsson, Makela et al. 2001). Post translational modifications
such as phosphorylation, acetylation, sumoylation etc., also modulate transcriptional
activation of nuclear hormone receptors (Germain, Staels et al. 2006). 
2.2.2. Non-Genomic Effects of Estrogen
Non-genomic effects of estrogen have been seen observed many tissues like uterus 
and neurons (Falkenstein and Wehling 2000; Nilsson, Makela et al. 2001; Sak and 
Everaus 2004). These occur quickly after estrogen treatment and cannot be blocked
by inhibitors of transcription. Studies have proposed that the non-genomic effects by 
estrogen may stimulate mitogen-activated protein kinase (MAPK) (Pedram, Razandi
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et al. 2006) and extracellular regulated kinase signalling or intracellular Ca2+ release 
(Mermelstein, Becker et al. 1996), due to specific plasma membrane estrogen 
Fig.3. Mechanisms of Estrogen Signalling: 17- Estradiol binds to ER which 
associate with and Estrogen Response Element (ERE) (1); E2 binds to ER which 
associate with Response Element (RE) through transcription Factor (TF)(2); E2 
mediates non-genomic effects(3); phosphorylation activates ERs and bind to ERE(4).
receptors. Nevertheless, the molecular mechanism for non-genomic effect is still 
under debate (Warner and Gustafsson 2006).  
2.3. Estrogen and Cardiovascular System
Estrogen is thought to protect against the cardiovascular disease by reducing plasma 
LDL cholesterol and increasing HDL cholesterol, and improving vasodilatation. It is 
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suggested that estrogen may also have direct cardiac protective effects (Mendelsohn 
2002). Estrogens have been shown to avert vascular dysfunction, promote 
vasodilatation in coronary arteries by increasing nitric oxide production through 
PI3K/Akt signalling and inhibits atherosclerosis (Haynes, Sinha et al. 2000; 
Krasinski, Spyridopoulos et al. 1997; Thompson, Pinkas et al. 2000). Estrogen 
receptors have direct anti-hypertrophic effect on the myocardium and estrogens
prevent also the development of hypertension in animal models. Estrogen (17-
Estradiol) reverses left ventricular hypertrophy (LVH) in postmenopausal women by 
hormone replacement therapy (Miya, Sumino et al. 2002). 17-Estradiol (E2)
effectively decreased angiotensin II (AngII) or endothelin ET1 induced hypertrophy 
and found hypertrophic signalling partially through PI3K (Pedram, Razandi et al.
2005). These animal studies suggest that estrogen replacement could reduce the risk 
of coronary artery disease in post menopausal women. However the data from two big 
clinical trials the heart and estrogen/progestin replacement study (HERS) and the 
world health initiative (WHI) indicate the therapy with combined estrogen and 
progestin replacement therapy is not effective in prevention of coronary heart disease 
(CHD) and might actually increase the risk of CHD in the first year (Hulley, Grady et 
al. 1998; LaCroix 2005; Mendelsohn and Karas 2007; Rossouw, Anderson et al.
2002).  On the other hand, several authors have criticized in particular the women’s 
health initiative studies claiming that the conclusions drown were not warranted due 
to the flawed design of this study.  Irrespective of the importance of estrogen in 
protecting against cardiovascular disease, the hormone will remain therapeutic for 
other indications. Its effects on the cardiovascular system need to be further 
characterized. 
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2.4. Gender Difference in Cardiac Hypertrophy
Clinical studies have shown gender differences in the model of adaptive left 
ventricular hypertrophy (LVH) in response to increased overload, such occurs in 
aortic stenosis and hypertension. Compared to male, female patients with similar 
conditions like aortic stenosis, cardiac performance is more commonly preserved and 
associated with smaller LV diameters. Gender differences occur also in hypertensive 
patients with LVH (Aurigemma and Gaasch 1995; Carroll, Carroll et al. 1992) In 
mice, pressure overload hypertrophy is attenuated by 17-estradiol (van Eickels, 
Grohe et al. 2001). Also it has been reported that cardiac contractile function is 
improved in many animal models (Dash, Schmidt et al. 2003; Kadokami, McTiernan
et al. 2000). High dose of  estradiol prevented development of post-MI remodeling as 
assessed LV dysfunction (Beer, Reincke et al. 2007). 
2.5. Estrogen Receptors in Cardiac Hypertrophy
Estrogens exert their function through estrogen receptors ER-  and ER- which are 
known to be expressed in the cardiovascular system. Studies employing transverse
aortic constriction (TAC) in estrogen receptor- knockout (ERKO) and estrogen 
receptor- knockout (BERKO) mice showed that the heart to body weight ratio is 
increased significantly in BERKO compared to ERKO and wild type littermate 
females indicating ER is attenuating the hypertrophic response to pressure overload 
(Skavdahl, Steenbergen et al. 2005). BERKO females showed increased mortality 
following myocardial infarction (Pelzer, Loza et al. 2005). Estradiol protects the 
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murine heart against LVH via ERß (Babiker, Lips et al. 2006). The protective effects 
of estrogen with respect to cardiac hypertrophy in young and senescent 
ovariectomized SHR rats showed the attenuation of cardiac hypertrophy only in 
young rats not in senescent SHR due to aging which is associated with increased 
cardiac hypertrophy in post menopausal women. 
2.6. Cardiac Hypertrophy 
The thickening of heart muscle is called cardiac hypertrophy. Continued increase in 
hemodynamic overload paves the route to cardiac hypertrophy. Which is considered 
as an adaptive response in order to maintain cardiac function (Taegtmeyer 2000a; 
Young, Laws et al. 2001) and normalize cardiac oxygen consumption (Grossman, 
Jones et al. 1975). It is known that continued pressure overload because of pathologic 
stimuli such as hypertension causes cardiac hypertrophy and heart failure. This 
pathologic cardiac hypertrophy is considered a maladaptive response. Cardiac 
hypertrophy also occurs due to physiologic stimuli like exercise training and it is 
termed as physiologic cardiac hypertrophy (Richey and Brown 1998b). Physiologic 
hypertrophy is not concomitant with adverse long term out comes (Burelle, Wambolt
et al. 2004; Frey and Olson 2003; Ritchie and Delbridge 2006). Pathological and 
physiological hypertrophic response to metabolic stress such as ischemia and 
reperfusion differ from each other (Allard, Schonekess et al. 1994; Bowles, Farrar et 
al. 1992; Richey and Brown 1998b). Physiologic cardiac hypertrophy is considered as 
adaptive in nature because post ischemic recovery is improved relatively to non-
hypertrophied hearts (Moore and Korzick 1995; Richey and Brown 1998b). The 
energy substrate metabolism is altered in cardiomyocytes due to pathological or 
physiological hypertrophic responses (Fig.4).  There is ample amount of evidence that 
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cardiac hypertrophy (both adaptive and maladaptive) is associated with alteration in 
energy substrate metabolism which may influence outcomes from ischemia and 
reperfusion (Anderson, Allard et al. 1990; Richey and Brown 1998b; Taegtmeyer 
2000a; Young, Laws et al. 2001).
2.7. Myocardial Energy Metabolism 
For normal cardiac function, energy is required in the form of adenosine tri phosphate 
(ATP) which is produced from fatty acids, glucose and ketone bodies (Bing, Siegel et 
al. 1953). In the adult myocardium, fatty acids are the major source of energy and 
account for 60-90% of total energy production (Shipp, Opie et al. 1961; Wisneski, 
Gertz et al. 1987). During fetal development, the main source of energy is glucose
(Ascuitto and Ross-Ascuitto 1996; Fisher 1984; Hoerter and Opie 1978). Acute 
cardiac work results in stimulation of metabolic process in an co-ordinated way and 
when the workload of the heart is two fold, oxygen consumption rate doubles; at the 
same time there is an immediate increase in the oxidation of glucose (Goodwin, 
Taylor et al. 1998).
Fig.4. Substrate preference of the heart. 
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2.7.1. Cardiac Glucose Metabolism
In cardiomyocytes, glucose is transported via a family of facilitative glucose 
transporters (GLUTs) (Fig.5). The heart expresses predominantly two glucose 
transporters namely GLUT4 and GLUT1 (Gould and Holman 1993; Pessin and Bell 
1992). GLUT1 is highly expressed during fetal life and decreases after birth (Castello, 
Rodriguez-Manzaneque et al. 1994). GLUT4 expression increases postnatally and 
reaches maximum in adulthood (Castello, Rodriguez-Manzaneque et al. 1994; 
Santalucia, Boheler et al. 1999; Santalucia, Camps et al. 1992).  Insulin and 
contraction are the two main stimuli for cardiac glucose uptake at physiological 
conditions. Ischemia, hypoxia and increased cardiac workload stimulate translocation 
of GLUT4 on to the plasma membrane (Egert, Nguyen et al. 1997; Sun, Nguyen et al.
1994; Till, Kolter et al. 1997).
Fig.5. Cardiac Substrate Metabolism
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2.7.1.1. Glucose Transporters
2.7.1.1.1. GLUT4
GLUT4 is predominantly expressed and highly regulated by insulin in the heart. 
Insulin increases glucose uptake facilitative via the glucose transporter GLUT4. 
Insulin stimulates translocation and activation of both GLUT4 and GLUT1 in heart 
Fig.6. Insulin Signalling Pathway.
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(Egert, Nguyen et al. 1999b; Zaninetti, Greco-Perotto et al. 1988).  GLUT4 regulates 
insulin dependent glucose uptake in heart (Abel 2004; Zorzano, Sevilla et al. 1997).
Among these transporters, insulin mediated GLUT4 translocation has been 
investigated immensely (Fig.6).  
2.7.1.1.2. GLUT1
GLUT1 is highly expressed in during fetal growth but down-regulate rapidly after 
birth.  GLUT1 has a role in basal glucose uptake (Smoak and Branch 2000). GLUT1
undergoes modest translocation to the sarcolemma with insulin and ischemia. During 
fasting, glucose and insulin levels are decreased with increased levels of free fatty 
acids that are associated with increased cardiac fatty acid uptake and decreased 
glucose uptake and GLUT1 levels (Kraegen, Sowden et al. 1993). Hyperinsulinemia 
causes increased levels of GLUT1 due to either increased glucose concentration or 
free fatty acids (Laybutt, Thompson et al. 1997). Studies with cardiomyocyte specific 
deletion of insulin receptor show reduced GLUT1 level and basal glucose uptake
providing a role for insulin on regulation of cardiac GLUT1 (Belke, Betuing et al.
2002). Left ventricular hypertrophy is associated with increased total GLUT1 levels 
and reduced GLUT4 levels but the levels of both transporters at plasma membrane are 
increased in the hypertrophied heart (Tian, Musi et al. 2001).
2.7.2. Metabolic Adaptation in Cardiac Hypertrophy
During cardiac hypertrophy, the myocardium undergoes a metabolic shift from fatty 
acid to glucose utilization, which reintroduces the fetal substrate metabolic design 
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(Bishop and Altschuld 1970; Taegtmeyer and Overturf 1988; Yonekura, Brill et al.
1985). Increased energy production is seen through glycolytic pathway compared to 
energy from fatty acid in hypertrophic heart and this shift causes lower oxygen 
consumption since 10% more ATP is generated from glucose than fatty acids per 
mole of oxygen  (Allard, Schonekess et al. 1994).  Myocardial energy utilization 
pathways also undergo alterations during cardiac hypertrophy. The re-entry of fetal 
metabolism and metabolic adaptation toward glucose occur before any change in 
cardiac mass in hypertensive animals (Taegtmeyer and Overturf 1988) and suggest 
that the change in metabolic substrate utilization to cardiac overload precedes cardiac 
hypertrophy. 
2.7.3. Cardiac Glucose Uptake in Insulin Resistance and Type II Diabetes
Hyperglycemia defines both types of diabetes and results from an absolute insulin 
deficiency in type 1 diabetes and tissue insulin resistance in type 2 diabetes
(American 1997; Association 1997) High circulating levels of glucose cause 
accelerated micro- and macro-vascular diseases (such as ischemic heart diseases, 
stroke, retinopathy, neuropathy and nephropathy) and increase morbidity and 
mortality in diabetic patients (Klein 1995). Diabetes is a strong independent 
cardiovascular risk factor, and the likelihood of death from cardiovascular causes is 
two to five folds higher in diabetics (Kannel and McGee 1979; Stamler, Vaccaro et al.
1993). Clinically, diabetes mellitus associated with a diabetic cardiomyopathy which 
is not directly attributable to microvascular disease, hypertension or obesity (Grundy, 
Benjamin et al. 1999; Hayat, Patel et al. 2004)
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Insulin resistance is a principal feature of type 2 diabetes and explained as 
inefficiency of insulin to stimulate glucose transport into peripheral target tissues  
(Petersen and Shulman 2002). There is a robust correlation between GLUT4 protein 
amount and the rate of glucose disposal. In diabetes, the insulin action and GLUT4
activity are impaired, GLUT4 deficiency leads to insulin resistance, hypertension, left 
ventricular hypertrophy and chronic heart failure (Anker, Ponikowski et al. 1997; 
Paolisso, De Riu et al. 1991; Reaven 1991). 
Insulin resistance is responsible for metabolically induced cardiac remodeling and 
caused by impaired glucose uptake relative to cardiac workload (Belke, Larsen et al.
2000; Desrois, Sidell et al. 2004).  As already discussed in the previous section,
glucose is supplied through GLUT4 and GLUT1 in cardiomyocytes and GLUT4 is 
most the abundant glucose transporter in the adult heart. GLUT4 translocates in to 
plasma membrane, in response to insulin, ischemia, hypoxia, and contraction (Till, 
Kolter et al. 1997). Decreased GLUT4 activity and expression  is suggested as one of 
the factors responsible for metabolic and contractile dysfunction in  the diabetic heart, 
where glucose uptake is compromised (Desrois, Sidell et al. 2004; Eckel and Reinauer 
1990).
2.7.4. Estrogen in Regulation of Glucose Homeostasis
Estrogen treatment in postmenopausal women had showed decreased blood glucose 
and improved insulin sensitivity (Crespo, Smit et al. 2002; Espeland, Hogan et al.
1998; Saglam, Polat et al. 2002). Estrogen reverses the effects of menopause on 
glucose and insulin metabolism by increasing insulin secretion from pancreas as well 
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as insulin sensitivity (Brussaard, Gevers Leuven et al. 1997; Stevenson, Crook et al.
1994). In mice, both ERKO and ArKO exhibit reduced glucose tolerance, insulin 
resistance and obesity (Heine, Taylor et al. 2000; Jones, Thorburn et al. 2001). ERKO 
mice also had shown decreased GLUT4 level in skeletal muscle that could account for 
impaired glucose uptake (Barros, Machado et al. 2006). The silencing of ER alpha in 
brain causes obesity, impaired glucose tolerance and decreased energy expenditure 
(Musatov, Chen et al. 2007). Estrogen treatment enhances insulin stimulated glucose 
uptake diabetic animals and reduced by ovariectomized (Louet, LeMay et al. 2004). 
However, the role of estrogen on cardiac glucose uptake is not kown. 
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3. Aim of the Study
The main aim of this study is to determine whether modulation in cardiac glucose 
uptake might contribute to the role of estrogens to prevent against development of 
cardiac hypertrophy. For this, female SHR animals at 12 weeks of age were either 
sham operated or ovariectomized (placebo) or ovariectomized treating 17β-estradiol 
over 6 weeks of period, then the following analyses was carried out.
1. Morphological analysis;  Analyzing body weight, heart weight, tibia length
2. Metabolic and Biochemical analysis, 
 Intra-peritoneal glucose tolerance test (IP-GTT) 
 Measurement of myocardial uptake of the positron-emitting 
glucose analogue 18F-2-deoxy-2-fluoro-D-glucose (FDG) and in-
vivo positron emission tomography (PET) in SHR
 Measurements of serum estrogen and insulin levels
3. Molecular analysis of cardiac glucose transporters (GLUT4 & GLUT1) 
expression and distribution in SHR rat, analyzed by using western blot and
immunofluorescence staining.
4. Examination of effects of estrogen on modulation of insulin signalling leading
to cardiac glucose uptake.
 Analysis of early insulin signaling molecule insulin receptor substrate 
(IRS-1) and its tyrosine phosphorylation were evaluated by western 
blot.
 Gene microarray analysis of SHR hearts using insulin signaling 
pathway specific genes.
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4. Material & Methods
4.1. Materials
Antibodies:
Solutions and Buffers:
For DNA electrophoresis
Agarose gel Agarose Ultrapure 2%
1x TAE
Ethidum bromide ( 0.5 μg/ml )
6x loading Dye (Agarose gel) 0.25 % bromphenol blue
30 % glycerol in water
0.25 % xylen cyanol
TAE ( 50x ) 242 g Tris base
57.1 ml acetic acid
100ml 0.5M EDTA
Primary Antibodies Provide/
Cat. No.
Mol Wt Dilution
Anti-GLUT1
(Rabbit Polyclonal)
Chemicon
#AB1340
~42-45 kDa 1 in 4000 (WB)
1 in 250 (IF)
Anti-GLUT4
(Rabbit Polyclonal)
Abcam
#ab654
~45 kDa 1 in 5000 (WB)
1 in 500 (IF)
Anti- Na+/K+ ATPase α-1
(Rabbit Polycloneal)
Upstate
#06-520
110 kDa 1 in 500 (WB)
Anti-IRS-1
(Rabbit Polyclonal)
Upstate
#06-248
~160 kDa 1 in 500 (WB)
Anti-phospho IRS-1 (tyr612)
(Rabbit Polyclonal)
Upstate
#07-846
~160 kDa 1 in 250 (WB)
Anti-4Ebp1
(Rabbit Polyclonal)
Cell Signalling
#9452
~15 to 20 
kDa
1:500 (WB)
Glyceraldehyde-3-phosphate
(Rabbit Polyclonal)
Upstate
#06-248
~37kDa 1 in 3000(WB)
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Add H2O to 1 liter, adjust pH to 8.5.
For RNA electrophoresis:
MOPS running buffer (10x) 41.86 g MOPS
6.8 g NaOAc.3H2O
3.8 g Na4EDTA
H2O to 1L
RNA electrophoresis 1 g Agarose
88 μml H2O DEPC
10 ml 10x MOPS buffer
2.3 μl EtBr
1.87 ml Formaldehyde
RNA loading dye 720 μl Formamide
160 μl 10xMOPS buffer
260 μl Formaldehyde
193 μl H2O
267 μl 6x Bromophenol blue DNA loading dye
Buffers:
1X PBS (Phosphate Buffered Saline) pH 7.4
NaCl 137.0 mM
KCl 2.7 mM
Na2HPO4 2H2O 1 mM
KH2PO4 1.5 mM
RIPA (Radio Immuno Precipitation Assay) Buffer (for 100ml)
NaCl 150.0 mM
Tris 50.0 mM
PMSF 1.0 mM
IGEPAL CA-630 1.0 %
Sodium deoxycholate 0.5 %
Sodium dodecyl sulfate 0.1 %
5x Electrophoresis Buffer pH 8.3 (for 1000ml)
Tris 124.0 mM
Glycin 960.0 mM
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SDS 0.1 %
Transfer Buffer (Western Blotting)
200 ml of 5x Electrophoresis + 200ml of Methanol (absolute) + 800 ml distilled H2O
Washing solution (Western Blotting)
1x PBS pH 7.4 5
Tween 20 (0.05 %)
Blocking solution (Western Blotting)
1x PBS pH 7.4 
Non-fat dried milk powder (5.0 %)
SDS-PAGE:
Separating Gel
Component 10 % 12 % 
(ml) (ml)
1,5 M Tris pH 8,8 5.0 5.0 
10 % SDS l 0.2 0.2 
Acrylamide+Bis acrylamide 6.67 8.0
(30 % - Stock) 
10 % APS 0.1 0.1
TEMED 0.01  0.01  
dH2O 8.02 6.69  
Stacking Gel
Component 5 % 
(ml)
1,5 M Tris pH 8,8 5.0 
10 % SDS l 0.2
Acrylamide+Bis acrylamide 6.67 
(30 % - Stock) 
10 % APS 0.1 
TEMED 0.01  
dH2O 8.02   
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4.2. Methods
4.2.1. Animals and Treatment
The total of 30 female spontaneously hypertensive (SHR) rats with 12 Weeks of age 
(with body weight of approximately 180-190 grams upon arrival) were obtained from 
Charles River Laboratories (Sulzfeld, Germany) and housed communally (5 animals 
per cage) under controlled temperature and lighting (12 hr light/dark cycle), fed with 
free food and water.   Arbitrarily, 20 animals were ovariectomized and the other 10 
animals were sham-operated. The experimental groups consist of Sham-operated 
(‘Sham’, n=10); Ovariectomized (‘Ovx’, n=10) placebo received; Ovariectomized + 
17β-estradiol (‘Ovx+E2’, n=10) which administered with 17β- estradiol at a 
concentration of 2 μg/kg of body weight/day. Initially, 17β- Estradiol compound was 
dissolved in absolute ethanol and the required final concentration has been made with 
peanut oil. For placebo, only peanut oil was given without any medicament. The 
animals were undergone 4 weeks of treatment and subcutaneous mode of injection 
was chosen. 
4.2.2. Positron Emission Tomography (PET)
The glucose uptake in female SHR rats (five animals from each group, 1.Sham, 
2.Ovariectomized and 3.Ovx+E2) was evaluated in-vivo by means of radio labelled
tracer 2-(18F)-fluoro-deoxyglucose (18FDG) and Positron Emission Tomography
scanner (Oxford Positron Systems, Oxford, UK).  18FDG is positron emitting glucose 
analogue which is injected to the animals and   positron the observation of glucose 
metabolism with a positron emitting glucose analogue can show the uptake of this 
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analogue displays in myocardium. After entering a cell it is phosphorylated by the 
hexokinase ((Phelps, Schelbert et al. 1983; Ratib, Phelps et al. 1982). Further 
breakdown of FDG-6-phosphate is inhibited in contrast to Glucose-6-phosphate.
Metabolism back to FDG is improbable because the required enzyme glucose-6-
phosphatase is not highly expressed in heart. FDG-6-phosphate is trapped in the cell 
since this molecule is too polar to pass the sarcolemma. The intracellular 
concentration of FDG is proportional to glucose utilisation of the tissue (Gallagher et 
al., 1978). Under fasting conditions FDG uptake is markedly suppressed by fatty 
acids. 
After 12 weeks of treatment, the animals were overnight fasted and the each rat were 
anesthetised with isofluorane / O2 for insertion of Insyte 24G catheters (~10min) 
and placed in Bollman’s restraining cage. Later, the rat was infused with glucose 
(G20) according to body weight at a concentration of 25mg/Kg/min for 15 minutes. 
One minute after end of glucose infusion, 18FDG (~15MBq) was injected in a bolus. 
The tissue paper was placed under the rat to collect any urine. Then rats were 
anaesthetized with isofluorane/O2 and placed in HIDAC for scanner. After 60 minutes
of (18F) FDG injection, HIDAC scan was started and scanned for a during of 15
minutes. The glucose levels were measured using Ascensia Elite Test Strips when the 
catheters were inserted and by tail vein puncture after injection (18F) FDG, 15 minutes
before and after the PET scan.
4.2.3. Morphometric Assessment:
The weight of whole body, heart, uterus, liver, kidney and the length of tibia were 
measured. These dissected wet tissues were blotted on paper towels before weighing. 
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The length of the tibia devoid of all soft tissue was measured.  The hear:body weight 
ratio was calculated by subtracting the heart weight by the body weight in grams. In 
the same way, the heart:tibia length ration also was calculated by diving the values of 
heart weight in grams by the values of tibia length in millimetres.
4.2.4. IP-GTT (Intra Peritoneal Glucose Tolerance Test)
After 4 weeks of treatment, the alteration of glucose excursion in Intra-peritoneal 
Glucose Tolerance Test (IGTT) was performed on all three different treatment groups. 
First, the rats were fasted overnight and glucose injected at a concentration of 1.5g per 
kilo gram of body weight by intra-peritoneally. The blood samples were withdrawn 
from venous blood from a small tail clip before and 10, 20, 30, 40, 50, and 60 minutes
after glucose infusion for the measurement of blood glucose levels. And also the
blood has been collected for serum Insulin assay.
4.2.5. Measure of Serum Insulin 
Insulin was assayed by using specifically synthesized antibodies against rat Insulin 
Radioimmunoassay (RIA) kit which obtained from DRG Systems, Marburg, 
Germany. This kit uses specifically synthesized antibodies against rat Insulin. 
4.2.6. Total Protein Isolation:
Approximately 50-100mg of tissue was taken in 200μl of RIPA buffer (including 
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protease and phosphatise inhibitors) and incubated for 15 minutes on ice. Following
homogenized (motor driven homogenizer) the tissue and centrifuged at 14000 rpm for 
10 minutes at 4°C. The resultant supernatant was considered as total protein. The 
protein concentration was measure by using BCA method. 
4.2.7. Subcellular Plasma Membrane Fractionation
The plasma membrane fraction was prepared as previously described (Fuller, Eaton et 
al. 2001).  In detail, the rat heart tissue was first incubated in high salt buffer (2 M 
NaCl, 20 mM Hepes, pH 7.4) on ice for 30 minutes, and then the tissue was retrieved 
by centrifugation at 1000g for 5 minutes, afterwards washed with Buffer A (10mM
Hepes, pH 7.4, 2 mM EDTA, pH 8.0, 1 mM MgCl2, 250 mM sucrose) and 
centrifuged once again. Using hand-held ground glass tissue grinder, the tissue was 
homogenized with buffer A (10ml Buffer A per 1g of tissue). Then the homogenates 
were centrifuged at 1000g for 5 minutes. The supernatants were centrifuged in a 
Beckman bench top optima TL ultracentrifuge using TLA 100.4 rotors. The resultant 
pellet was considered as plasma membrane which was resuspended with buffer A and 
supernatant was cytosolic fraction. 
4.2.8. Western Blot
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis:
Prior to SDS-PAGE analysis, the protein samples were denatured by adding 2X 
Sample buffer (Lammeli Loading buffer) at a ratio of 1:1 and were boiled at 95°C for 
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10 minutes. Then the samples were run on 8-10% SDS- PAGE gel using 1X Tris-
Glycine running buffer. (manniatis). After resolving the proteins on the gel, 
immediately proceeded with wet transfer by submerging the sandwich 
(sponge/paper/gel/membrane/paper/sponge) in 1X transfer buffer and applying 
electrical field allows the proteins from the gel blotting on the nitrocellulose 
membrane.  Then the membrane was blocked with blocking solution (5% non- fat 
milk powder prepared in PBS/Tween 20 buffer) for 1 hour incubation under agitation. 
This blocking step prevents the non-specific binding of primary/secondary antibody to 
the membrane. After incubation, the membrane was washed with PBST buffer for 3 
times with 10 minutes interval.  The primary antibodies were diluted in blocking 
solution. Then, the membrane was incubated with the primary antibody solution for 
overnight at +4°C with gentle agitation. The membranes were washed 4-5 times with 
PBST while agitating for overall of 30-40 minutes. The membranes were incubated 
with HRP-conjugated secondary antibodies (diluted with blocking solution) for 1 hour 
at room temperature. Finally the membranes were again washed 4-5 times with PBST 
while agitating for overall of 30-40 minutes. Then the membranes were soaked in 
Enhanced Chemiluminescence Reagent (ECL obtained from GE Bioscience) that
elicits a peroxidase-catalyzed oxidation of luminol and subsequently enhanced
chemiluminescence, where the HRP labeled protein is bound to the antigen on the 
membrane. The resulting light was detected on an X-ray film. 
4.2.9. Immunofluorescence Staining
The frozen rat hearts which embedded in tissue tek (an OCT compound obtained from 
Sakura Finetek Germany GmbH) were cut in to 3 micron sections in a cryostat and 
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mounted on the slides then stored at 80°C until use. For the immunofluorescence 
staining, the sections were first washed (Throughout the protocol, washing step 
involves three times of wash using PBS buffer at 10 minutes interval) and then fixed 
with 4% paraformaldehyde (PFA) for 15 min. Again wash with PBS buffer, the
section slides were incubated at room temperature for 1hr with the goat serum (diluted 
in PBS) in order to prevent non specific binding of primary or secondary antibodies. 
Then serum was removed and the sections were incubated with primary antibodies 
with either GLUT4 (1 in 250) or GLUT1 (1 in 200) overnight at 4°C by placing the
slides in a humid chamber to prevent dehydration.  Some slides were treated in the 
similar way without primary antibody and considered as a negative control. After 
overnight incubation, let the slides come down to room temperature and washed. Then 
the slides were incubated with goat anti- rabbit AlexaFluor 594 (Molecular Probes, 
Invitrogen) secondary antibody including negative control slides.  After a subsequent 
time, all the sections were washed and stained with Wheat Germ agglutinin which 
was used as a marker for plasma membrane (requires 10mins of incubation with 
Fluorescent Wheat germ agglutinin- Alexa Fluor 488 which obtained from Molecular 
Probes, Invitrogen at a dilution of 1 in 200 from 1ug/ul concentration). Followed by 
agglutinin staining, the slides were washed and incubated with DAPI for 30min and 
final wash was performed. At the end, the slides were mounted in Vectashield® 
mounting medium (Vector Labs) and covered with cover slips and the cover slip 
edges were sealed with nail polish.  
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4.2.10. RNA Isolation
The total RNA from rat heart was extracted according to manufacture’s instructions in 
Trizol reagent (Invitrogen).  In brief, the frozen rat myocardial tissue (~50mg) was 
homogenized in 1ml Trizol reagent until the suspension becomes homogenous and 
subsequently centrifuged at 15000rpm for 10 minutes at 4°C in order to eliminate the 
insoluble materials (extracellular membranes, polysaccharides and high molecular 
weight DNA). Then supernatant (containing RNA and protein) was recovered and 
incubated at room temperature for 5 minutes to ensure complete dissociation of 
nucleoprotein complexes and then 200μl of Chloroform was added and incubated at 
room temperature for 15 minuets and the separation of three layers (Colourless upper 
phase containing RNA, interphase containing DNA, red organic phase containing 
protein) has been achieved by centrifugation at 15000 rpm for 15 minutes at 4°C. The 
colourless aqueous phase has been taken separately and 1 volume of isopropanol has 
been added and mixed and allowed it to stand at room temperature for 8minutes. After 
centrifugation at 15000rpm for 20 minutes at 4°C, RNA precipitates to form a pellet 
on the side and bottom of the tube and the RNA pellet was washed by adding 1ml of 
75% ethanol centrifugation at 15000 rpm for 20 minutes at 4°C. After complete 
removal of ethanol, the RNA pellet has been dissolved with 25ul of 0.1% DEPC 
treated H20 and store it at 80°C until further use. The concentration and purity of the 
isolated total RNA was determined by absorbance measurement, and the integrity of 
ribosomal RNAs that were demonstrated by running it on 1% agarose gel 
electrophoresis.
4.2.11. Hexokinase Assay 
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Hexokinase is an enzyme that catalyses glucose to glucose phosphate was evaluated 
by measuring the rate of reduction of NADP+ as previously described (Swislocki, 
Burgie et al. 2002). First, 100μg of protein was dissolved in 2ml of reaction buffer 
(40mM HEPES, 0.8mM EDTA, 7.5mM MgCl2, 1.5mM KCl, 2.5mM ATP (2Na), 
10mM Creatine Phosphate (2Na), 0.9 IU/ml Creatine Phosphokinase, 0.7 IU/ml 
glucose-6-phosphate dehydrogenase, and 0.4mM NADP+, pH 7.4). Then 100μl of 
this reaction buffer containing sample was taken in 96well plate and assay was 
initiated by adding D-glucose (at a final concentration of 1.0mM) and the production 
of NADPH were measured at 340 nm per minute at 25°C.  The samples with out 
glucose and reaction buffer alone were considered as a negative control.
4.2.12. Oligo GEArray® Rat Insulin Signaling Pathway Microarray
Oligo GEArray® Rat Insulin Signaling Pathway Microarray kit was obtained from 
SuperArray Bioscience Inc (Bethesda, MD, USA). This Oligo GEArray is a pathway-
focused DNA microarray. The nylon membrane array matrix is a permeable support 
with a high DNA binding capacity. The designed 60-mer oligonucleotide probes 
printed on each microarray minimizes any cross-hybridization between spots on the 
same array despite the representation of closely related members of the same gene 
families. The target synthesis and labelling protocol provides un-biased linear RNA 
amplification in a simple one-tube protocol. The biotinylated cRNA target and the 
carefully designed oligonucleotides on the array correspond to the same 3'-biased 
gene-specific sequences permitting efficient and specific hybridization. The oligo 
GEArray has been optimized for chemiluminescence detection method, which allows 
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the use of either X-ray film or a CCD-camera imaging system for image acquisition. 
This Oligo GEArray® Rat Insulin Signalling Pathway Microarray contains 127 
oligonucleotide probes (Detailed array layout, fig.18) representing genes associated 
with insulin receptor and target genes in the insulin signalling pathway. And the genes
involved in carbohydrate, protein and lipid metabolism and members of the PI3K and 
MAPK Pathways and other related biological responses are also embedded.  The total 
RNA was isolated from the SHR rat heart tissues by agen Inc., Valencia, CA, USA), 
and 3g RNA was used as a template to generate Biotin-16-dUTP-labeled cDNA 
probes according to the manufacturer's instructions. The cDNA probes were 
denatured and hybridized at 60°C with the SuperArray membrane, which was washed 
and exposed with the use of a chemiluminescent substrate. To analyze the SuperArray 
membrane, we scanned the membranes via a CCD camera and imported it into Adobe 
Photoshop as a TIFF file. The image file was inverted, and the spots were digitized 
with the use of GEarray analyzer program (SuperArray Corp.), and normalized by 
subtraction of the background as the average intensity value of 2 blank spots. The 
averages of two GAPDH spots were used as positive controls and set as baseline 
values with which the signal intensity of other spots was compared.
4.2.13. Statistics 
Statistical analysis was performed using one way ANOVA, Bonferroni t-test. The 
results are presented as mean values of each treatment group ± SEM. The p<0.05
values were considered as statistically significant. The statistical analysis was per 
perfomed using sigmastate 32 software (SPSS Inc)
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5. RESULTS
5.1. Measurement of Myocardial Glucose Uptake
The effect of estrogen on myocardial glucose uptake in SHR rats was measured by 
18F-fluoro -2-deoxy-d-glucose positron emission tomography (FDG-PET). After two 
hours of food withdrawal with free access to water, the rats were anaesthetized with 
isofluorane / oxygen  for insertion of Insyte 24 G catheters about 10mins and placed 
in bollman’s restraining cage and infused with glucose at concentration of  
25mg/kg/min for 15 minutes for a total of 16 to 17mins. One minute after the end of 
glucose infusion 18F FDG (approximately 15MBq) was injected via tail vein
Fig.7. PET images obtained 60mins after injection of 15 MBq [18F] FDG to sham (A),
ovx (B) and E2 treated (C) SHR rats via a tail-vein catheter. Cardiac [18F]
fluorodeoxyglucose uptake in SHR rats was visualized by a quadHIDAC PET scanner 
following. Representative images of sham, ovx and ovx+E2 are shown. (PET analysis 
were performed in collaboration with Dr.Marilyn P. Law, Department of Nuclear 
Medicine, University Hospital, Muenster, Germany)
Sham Ovx Ovx+E2
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catheter and urine was collected in tissue papers before PET scanning. Sixty minutes 
after 18F FDG injection the HIDAC scan was started and scans were performed for 
15 minutes. Figure.7 shows PET images from sham operated, ovx and ovx+E2 SHR 
animals. FDG-PET revealed a significant difference in myocardial glucose uptake 
between sham, ovx and ovx+E2 SHR animals (Fig.7). Myocardial FDG uptake was 
substantially enhanced by E2 treatment compared to ovariectomized SHR animals. In 
house software was used to reconstruct the HIDAC data and to compute the total 
radioactivity in the left ventricular wall (HIDAC counts per second (cps) (A) cps), and 
septum (HIDAC counts per second (cps) (A) cps) and the volume of the left ventricle 
wall and septum [V] ml). The difference in the radioactivity injected, the activity cube 
drawn round the rat [R] cps) and round the urine tubes ([U] cps) were calculated for 
normalization of the data and the sum of the cps in these cubes ((R) + (U)) were 
calculated. 
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Fig.8. Myocardial FDG uptake in SHR.  (a). The myocardial FDG uptake (counts 
per second per ml) indicates the improved glucose uptake by E2 treatment. (b). 
Indicate the FDG uptake index, expressed as %dose/l00 ml tissue of myocardium in 
SHR. Myocardial 18F FDG uptake in ovariectomized SHR animals was lower than 
sham and E2 treated animals (P0.05).
5.2. Influence of E2 treatment on morphology in SHR animal
The increased body weight due to ovariectomy in SHR was abolished by 17β-
estradiol treatment effectively which was comparable to sham operated rats. As 
shown in the figure 9, there was significant difference among the following treatment 
groups. Sham vs Ovx (p<0.001), ovx vs ovx+ E2 (p<0.001) and Sham vs Ovx+E2 
(p<0.001). The number of the animals from each group were 8 (Sham), 9 (Ovx) and 
10 (Ovx+E2).
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Fig.9. Body weight of SHR rats. The solid bar represents body weight of SHR rat groups 
of sham operated, ovariectomized SHR treated with placebo received, and 17β- estradiol
(E2). Each bar represents mean ± SEM * p0.001 and **p0.001.
Uterus weight was measured to evaluate the efficacy of estrogen treatment in-vivo.
Uterus weight (fig.10) was decreased significantly in ovariectomized rats due to 
endogenous estrogen deprivation when compared to sham operated and 17β- estradiol 
substituted ovariectomized SHR 
Fig.10. Uterus weight of Ovariectomized and E2 treated ovariectomized animals.
SHR rats were sham operated (sham), ovariectomized (ovx) placebo received, 
ovariectomized with 17β-estradiol treated. Ovariectomy resulted in reduced uterus 
**
*
0
50
100
150
200
250
300
350
400
450
sh
am Ov
x
Ov
x +
 E
2
U
te
ru
s
 W
t 
(m
g
)
Results 38
weight, which was blocked by estrogen treatment. Each bar represent uterus weight 
mean ± SEM. *P< 0.001 and ** P< 0.001.
Increased heart weight is the hallmark of cardiac hypertrophy. Previous animal studies 
supported that E2 has anti hypertrophic action, so the degree of cardiac hypertrophy in 
the present study was calculated by normalizing heart weight to tibia length. As seen 
from figure 3, cardiac mass was increased in ovariectomized SHR rats compared to 
sham operated controls. After E2 treatment, heart weight was significantly reduced. 
Fig.11. Absolute and relative heart weight of SHR rats.  Absolute heart weight of
SHR rats (A) and the relative heart weight (B). The absolute and relative heart 
weights were increased in ovx SHR. Each solid bar represents mean mean ± SEM 
(n=8 (sham), n=9 (ovx) & n=10(ovx+E2).   
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5.3. Hormone Measurements
Serum estrogen and insulin level in ovariectomized and estrogen- treated female SHR 
rats were measured by radioimmunoassay as mentioned in method section. 
Ovariectomy of SHR rats resulted in significant reduction of endogenous estrogens 
compared to sham operated animals. Estrogen levels in ovariectomized rats were 
lower comparing to sham operated rats (1.3±0.10 vs. 12.2±2.6 pg/ml, p0.05)
(fig.12). 
Fig.12. Serum Estrogen and Insulin levels in SHR rats. Serum estradiol (A) and 
insulin (B) levels from sham, ovariectomized (placebo) and E2 treated SHR rats. Each
bar represents mean ± SEM, * p < 0.05.
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17β- estradiol treatment resulted in increased serum estrogen concentrations 
compared to ovariectomized animals. Insulin levels were increased 5 fold in E2 
treated SHR rats compared to ovariectomized (0.31±0.08 Vs 1.64±0.35ng/dL, 
p0.05). There were no significant difference in serum insulin levels between sham 
operated group and ovariectomized SHR.
5.4. IP-GTT (Intra Peritoneal Glucose Tolerance Test)
To investigate the effect of ovariectomy and E2 treatment on insulin sensitivity in 
SHR rats, intra-peritoneal glucose tolerance test (IP-GTT) was performed on all three 
different treatment groups after 12 weeks of treatment. As shown in the fig.13, blood 
glucose levels in the all the three groups increased to a maximum at around 25
minutes and declined slowly thereafter.  There was no significant change in blood 
glucose levels in all the three groups.
Fig.13. Intra-peritoneal glucose tolerance test (IP-GTT) in sham, ovx+placebo and 
E2 treated SHR animals. Values are mean ± S.E.M. 
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5.5. Effect of E2 on Expression Levels of Total Content of Glucose Transporters 
(GLUT4 and GLUT1) in SHR animals
The translocation of glucose transporters from the perinuclear compartment to the 
plasma membrane is a prerequisite for glucose uptake.  The total content of glucose 
transporters and subcellular distribution was assessed by western blot and 
immunofluorescence staining. As seen in the figure 14 (A) and 5(B), 17ß-estradiol 
treatment did not alter total content of either GLUT4 or GLUT1 in SHR rat hearts.
A)
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Fig. 14. Western blot analysis for total GLUT4 and GLUT1. A) The total protein 
from heart tissues of SHR animals of different treatment groups sham operated 
ovariectomized (ovx) and ovariectomized plus E2 treated (ovx+e2) groups were 
resolved in SDS-PAGE and consequently subjected to immunobloting with anti-
GLUT4 and GLUT1. GAPDH was used as a loading control. A) GLUT4 levels and 
B) GLUT1 Levels.  The values are mean ± SEM expressed as arbitrary densitometric
units (ADU).
5.6. Effect of Estrogen on Sub-cellular Translocation of GLUT4 and GLUT1 in 
SHR rat hearts
To investigate whether estrogen influences GLUT4 and GLUT1 translocation to 
plasma membrane, the cytosol and plasma membrane fractions from SHR hearts were
analyzed by western blot. There was no difference of either GLUT4 or GLUT1 
translocation among the treatment groups (Fig. 15(a-d)). 
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Fig.15. Western blot analysis of GLUT: Cytosolic and plasma membrane GLUT4
and GLUT1 protein levels (A-D) were examined in the SHR heart. Equal amounts of 
proteins were resolved on 10% SDS-PAGE and blotted with respective GLUT4 and 
GLUT1 antibodies.  All the blots were also blotted with respective control antibody to 
GAPDH (Cytosolic) or Na+K+ATPase-α-1 (Plasma membrane) CDEF show 
densitometry measurements of protein bands in A-D respectively.
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5.7. Immunofluorescence staining of GLUT4 and GLUT1 in SHR rat heart
Immunostaining for GLUT4 and GLUT1 on SHR heart tissue sections from sham, 
ovariectomized and E2 treated groups were analyzed as described in methods section. 
As seen from fig 16 (a), GLUT4 fluorescence signal (Green) was observed throughout 
the cytoplasm and strong in the plasma membrane in all three experimental groups 
which indicates no change in translocation pattern of GLUT4 by estrogen. Agglutinin
Fig.16(a)
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Fig. 16. Immunofluorescence staining of GLUT4 and GLUT1 in SHR heart. The 
distribution of GLUT4 (a) and GLUT1(b) in the heart tissue from Sham operated, 
ovariectomized and E2 treated SHR was analyzed by immunofluorescence staining 
and fluorescence microscopy using specific antibodies directed against GLUT4 and 
GLUT1 (in green),  agglutinin (in red). 
(red) was used as a plasma membrane marker. Slides without primary antibodies were 
employed as a negative control. Agglutinin was used as a plasma membrane marker.
GLUT1 staining (fig.16 (b)) showed its distribution throughout the intracellular space.
In overall, sub-cellular distribution of GLUT4 and GLUT1 was not changed by 
estrogen.  
Fig.16(b)
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5.8. Effect of E2 on IRS-1 and Tyrosine Phosphorylation
To investigate whether estrogen treatment affects cardiac insulin signalling molecules
in SHRs, insulin receptor substrate (IRS-1) and its tyrosine phosphorylation were 
examined. Total protein from each group was subjected to western blot analysis with 
specific antibodies to total IRS-1 and phosphor IRS-1 (aa612).  
Fig.17. Effect of E2 on IRS-1 and tyrosine phosphorylation of IRS-1. The total 
protein from heart tissues of SHR animals with different treatment groups Sham 
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operated ovariectomized (ovx) and ovariectomized plus E2 treated (Ovx+e2) groups 
were resolved in SDS-PAGE and consequently subjected to immunobloting with anti-
IRS-1 and pIRS-1 (tyr 612). GAPDH was used as a loading control. 7(A) represents 
IRS-1 levels and 7(B) Levels of pIRS-1. The values are mean ± SEM expressed as 
arbitrary densitometric units (ADU) plotted.
As shown in the fig 17(a) & (b), there was no significant change was seen in either the 
total IRS-1 protein or tyrosine phosphorylation levels in SHR rats in all treatment 
groups. 
5.9. Microarray analysis:
OligoGE microarray analysis was performed using group wise pooled RNA (sham, 
ovx, and ovx+E2; n=6) as described in the methods section using insulin signaling 
pathway specific array (Fig 18 (A) - Gene Layout and Gene Group) to assess changes 
byE2 substitution on Insulin signaling pathway genes in SHR rat heart. Seven genes 
were up-regulated by E2 treatment which has more than 1.5 fold differences. Genes 
up-regulated by E2 treatment are involved in protein biosynthesis, Eif4ebp1; PI-3K 
pathway, Frap1; MAPK pathway, Mapk21,Raf1 & Ercc1; SREBP1 component, 
Fbp1; Glucose Metabolism, Gpd1.
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Fig.18.Gene Expression Profile in SHRs.  RNA  from ovariectomized and E2 
treated rat heart were tagged with biotin, amplified, and hybridized with insulin 
signaling pathway specific microarray as explained in methods section. The 
autoradiograph images of the microarray are shown here as ovariectomized and E2 
treated (fig.18(A)). The autoradiograph images were analyzed using web-based 
GEArray Expression Analysis Suite software. Qualitative analysis of gene expression 
changes comparing ovariectomized and E2 treated group. Color representation (fig. 
18(B) of relative expression levels of genes encoding insulin signaling pathway genes 
in the SHR rat heart from ovariectomized and E2 treated animals. A color code key 
for the magnitude of gene expression is shown at the bottom (B).The differentially 
gens expressed are listed in table 2.
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Table 2. Genes up-regulated by E2 treatment in SHR heart
Gene Name
GenBankTM
accession 
number
Fold
Difference Function
Eif4ebp1
(Eukaryotic translation 
nitiation factor 4E binding 
protein 1)
NM_053857
+2.29
Forms a complex with eukaryotic 
initiation factor-4E (eIF-4E) which 
responsible for protein synthesis and 
also an intracellular target for insulin 
and growth factors
Frap1
(FK506 binding protein 12-
rapamycin associated
protein 1)
NM_019906 +1.97
Binds the complex formed by the 
immunosuppressive drug rapamycin 
and its receptor FKBP12; may play a 
role in the cell cycle G1 to S transition.
Map2k1
(Mitogen activated protein 
kinase kinase 1)
NM_031643
+1.71
A kinase that activates Mapk3 (Erk1) 
and Mapk1 (Erk2) kinases
Raf1
(V-raf-1 murine leukemia viral 
oncogene homolog 1)
NM_012639
+1.68
Acts as a mitogenic protein kinase; 
mutant forms may play a role in 
transformation
Fbp1
Fructose-1,6- biphosphatase 1
NM_012558 +1.64 Catalyzes the hydrolysis of fructose 
1,6-bisphosphate to fructose 6-
phosphate and inorganic phosphate in 
gluconeogenesis
Gpd1
Glycerol-3-phosphate 
dehydrogenase 1 (soluble)
NM_022215 +1.68
Target gene of PPAR, involved in 
glycolysis
Ercc1_predicted
Excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 1 (predicted)
XM_214833 +1.78
Target gene in MAPK pathway
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5.10. Hexokinase Activity
Hexokinase (HK; EC 2.7.1.1) is required for glucose metabolism in SHR hearts was 
measured as described in the methods section. As shown in the figure.19, the reduced 
hexokinase activity (the amount of production of NADPH) in ovariectomized SHR 
was significantly increased by E2 treatment (*p0.010).
            
Fig.9. Total activity of hexokinase in heart homogenates from SHR rats of different 
treatment groups were measured spectrophotometrically by measuring the amount of 
NADPH formed per minute at 340nm. The solid bar represents the amount of reduced 
NADP+ levels. Each bar represents mean ± SEM. 
5.11. Western blot analysis of 4Ebp1:
The differentially expressed genes Frap1 (mTOR), and Eif4bp1 were up-regulated in 
E2 treated group. These two genes are belonging to mTOR signalling pathways which 
*
0
0.1
0.2
0.3
0.4
0.5
0.6
Sh
am
Ov
x+
Pl
ac
eb
o
Ov
x 
+ 
E2A
m
o
u
n
t 
o
f 
R
ed
u
ce
d
 N
A
D
P
 L
ev
el
s
Results 53
Fig. 10. Western blot analysis of 4E-BP1. The total protein from SHR (sham, ovx 
and ovx+E2) was subjected to immunoblotting with anti-4Ebp1 antibody. The 
position of the 3 forms of 4E-BP1 from unphosphorylated (α) to hyperphosphorylated 
(γ) is indicated.
regulates protein synthesis. One of the effectors of mTOR is 4E-BP1. On 
phosphorylation of 4E-BP1 results in release of eIF4E, allowing increased formation 
of the eIF4F translation factor complexes leads to increased protein synthesis. The 
increased level of 4E-BP1 phosphorylation in ovariectomized SHR was reduced by 
E2 treatment. The phosphorylation of 4E-BP1 is known to be critical for the 
development of cardiac hypertrophy in response to pressure overload (S Sharma et al,
2007).
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6. Discussion
This study primarily demonstrates that estrogen modulates myocardial glucose 
utilization in female spontaneously hypertensive rat (SHR). The myocardial glucose 
uptake in intact versus ovariectomized female SHR with non-selective estrogen 17β-
estradiol and without (placebo) was evaluated by using 2-[18F-fluorodeoxyglucose 
and positron emission tomography; the data indicated that the 17β-estradiol exert 
significant increase of myocardial glucose uptake. Estrogen deficient ovariectomized 
SHR demonstrated reduced myocardial FDG accumulation compared to intact SHAM 
controls and it was normalized by 17β-estradiol treatment.
Cardiac hypertrophy induced by pressure overload such as hypertension is a 
characteristic increase in cardiac muscle mass and alterations in the structure of the 
heart and is an independent risk factor for cardiovascular diseases. Cardiac 
hypertrophy is also associated with abnormalities in energy metabolism, the chief 
myocardial energy source switches from fatty acid to glucose, a regression to the fetal 
energy substrate preference pattern (Panidis, Kotler et al. 1984; Richey and Brown 
1998a; Takano, Zou et al. 2002). The rate of glucose oxidation are reduced and also 
the amount of ATP or high-energy phosphates in the myocardium in cardiac 
hypertrophy and failure and predicted that it might be very important contributors to 
contractile dysfunction, and it is consider that efficiency of the heart is improved as
long as glucose can be oxidized (Bishop and Altschuld 1970; Depre, Vanoverschelde
et al. 1999; Opie 1968; Taegtmeyer 2000b; van der Vusse, Glatz et al. 1992);(Zhang, 
Merkle et al. 1993). In hypertrophied heart, insulin dependent glucose uptake is 
impaired but with increased basal glucose uptake (Bishop and Altschuld 1970; Christe 
and Rodgers 1994; Kagaya, Kanno et al. 1990). It has been shown that cardiac 
Discussion 55
specific ablation of major cardiac glucose transporter insulin-dependent GLUT4
causes development of cardiac hypertrophy. Collectively, these observations indicate 
that the disturbance in cardiac glucose utilization and oxidation is critical for cardiac 
function which causes cardiac hypertrophy. Women have lesser prevalence for 
cardiac hypertrophy than men but risk of heart disease increases in postmenopausal 
women compared to age matched males (Agabiti-Rosei and Muiesan 2002). In animal 
studies already have shown that estrogen prevents development of cardiac 
hypertrophy and 17β-estradiol or selective estrogen receptor agonist (16α LE2) in 
ovariectomized SHR efficiently attenuate cardiac hypertrophy by reducing cardiac 
mass and increased cardiac output and contractility (Jazbutyte, Arias-Loza et al. 2008; 
Pelzer, Jazbutyte et al. 2005). For this improvement of cardiac performance energy 
metabolism must be maintained. In the present study myocardial FDG accumulation
showed that the reduced glucose uptake by ovariectomy was normalized by 17β-
estradiol treatment in SHR. With the beneficial effects of 17β-estradiol in preventing 
development of cardiac hypertrophy in female SHR, the present data provide a novel 
mechanism to explain for direct protective role of estrogen in cardiac hypertrophy. In 
order to explain whether this difference in myocardial glucose accumulation is due to 
changes in blood glucose levels or involvement of intrinsic changes in cardiac 
metabolism, intra-peritoneal glucose tolerance tests were performed.  Glucose 
responses during IP-GTT were similar between the treatment groups. Ovariectomy 
did not alter in vivo glucose tolerance in SHR. However, the reduced serum insulin 
levels were observed in ovariectomized SHR and were normalized by E2 treatment. 
Previous studies have stated that any disturbances in female gonad hormone levels 
that occur with gestational diabetes mellitus and polycystic ovarian syndrome result in 
impaired glucose tolerance and insulin resistance. Estrogen treatment in 
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postmenopausal women showed improved insulin sensitivity (Crespo, Smit et al.
2002; Espeland, Hogan et al. 1998; Saglam, Polat et al. 2002). Estrogen reverses the 
effect of menopause on glucose and insulin metabolism by increasing insulin 
secretion from pancreas as well as insulin sensitivity (Brussaard, Gevers Leuven et al.
1997; Stevenson, Crook et al. 1994). In mice, Both ERKO and ArKO exhibit reduced 
glucose tolerance, insulin resistance and obesity (Heine, Taylor et al. 2000; Jones, 
Thorburn et al. 2001). ERKO mice also showed decreased GLUT4 in skeletal muscle 
level that could account for impaired glucose uptake (Barros, Machado et al. 2006). 
Estrogen treatment enhances insulin stimulated glucose uptake in diabetic animals and 
reduced by ovariectomy (Louet, LeMay et al. 2004). The alteration in insulin levels 
may account for increased myocardial glucose uptake by estrogen in SHR hearts. 
Further it raises the question whether the difference in glucose transporters are 
responsible for the increased FDG uptake by E2. Many studies revealed that glucose 
transport through the plasma membrane is a rate-limiting step of myocardial glucose 
utilization and glycolytic flux (King and Opie 1998; Manchester, Kong et al. 1994).
Glucose is an important metabolic substrate for the heart and assumes increased 
importance in the response of the heart to ischemia and in the adaptation of the heart 
to cardiac hypertrophy. Secondly, the heart demonstrates a unique ability to alter its 
substrate utilization on the basis of changes in substrate supply and cardiac work. 
Thus understanding the factors that regulate glucose entry into the heart will increase 
our understanding of cardiac physiology and pathophysiology. Glucose transported in 
to cardiomyocytes through glucose transporters GLUT 4 and GLUT 1 (Mueckler 
1990). GLUT4 is major glucose transporter localized in the cytosol and  translocation 
in to plasma membrane to facilitate the glucose in response to insulin (Slot, Geuze et 
al. 1991), workload, ischemia, and hypoxia (Sun, Nguyen et al. 1994). Insulin bind 
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with its receptor stimulate the tyrosine phosophorylation of beta subunit of insulin 
receptor (Lee and Pilch 1994) This inturn activates tyrosine phosphorylation of many 
other insulin receptors substrates  and  interact with phosphatidylinositol 3-kinase 
(PI3K), in turn  activates Akt, a downstream serine/threoninekinase that stimulates
uptake of glucose through glucose transporter GLUT4 translocation in to the plasma 
membrane (Cong, Chen et al. 1997). The activity of GLUT4 is controlled by insulin
in cardiac muscle in which glucose transport needs to be rapidly and markedly 
enhanced (Kahn 1992; Slot, Geuze et al. 1991). GLUT-1 is evenly distributed 
between the plasma membrane, whereas GLUT-4 is almost entirely stored in an 
intracellular pool (James, Strube et al. 1989; Kahn, Charron et al. 1989; Slot, Geuze
et al. 1991). When insulin levels are less, GLUT-4 is re-sequestered in intracellular 
vesicles (Holman and Cushman 1994). A reduction in GLUT-4 mRNA and protein is 
thought to be a mechanism for insulin resistance in various models of diabetes, and it 
has been associated with lower myocardial glucose uptake (Garvey, Hardin et al.
1993; Garvey, Maianu et al. 1991; Sinha, Raineri-Maldonado et al. 1991). In the 
present study, there is no change on GLUT4 and GLUT1 protein expression or 
translocation to the sarcolemma in SHR. A large amount of GLUT1 in the 
myocardium is localized to the sarcolemma and is considered to be responsible for 
basal glucose transport, even though its translocation can also be induced by stimuli 
that provoke GLUT4 accumulation in the sarcolemma (Egert, Nguyen et al. 1999a; 
Fischer, Thomas et al. 1997; Young, Renfu et al. 1997). Any defect in insulin 
signaling will lead to insulin resistance. Insulin resistance is a major complication for 
the development of hypertension, LVH and dysfunction, and HF, will causes the 
defect in glucose metabolism and will cause sever metabolic changes cardiac muscles. 
In present study there was no difference between intracellular and plasma membrane 
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localization or protein levels of GLUT4 or GLUT1 levels SHR myocardial tissue was 
not altered by estrogen. There are some studies which could explain this difference, 
the inactive GLUT4 localized on plasma membrane without any glucose transport 
activity since mechanism of glucose uptake through GLUT4 is precisely controlled in 
time and space in insulin signal transduction (Calderhead, Kitagawa et al. 1990; 
Holman, Kozka et al. 1990; Joost, Weber et al. 1987; Palfreyman, Clark et al. 1992).
And also there were no changes on initial step insulin signaling molecules like IRS-1 
and its phosphorylation in insulin induced glucose uptake in SHR hearts. These 
findings suggest that that GLUT4 is not rate limiting for increased glucose uptake 
observed in E2 treatment. 
The efficiency of ovariectomy and estrogen treatment in Spontaneously Hypertensive 
rat has been assessed. In ovariectomized SHR rats, serum levels of estrogen were 
significantly decreased in contrast to sham operated animals and serum estrogen 
levels brought back by estrogen treatment in SHR animals. And uterus weight 
provides valuable information not only about estrogen substitution efficacy but also 
about the quality of ovariectomy. Systemic estrogen levels have long been recognized 
to modulate body mass and body mass composition in humans and in whole variety of 
animal models; decreased estrogen prevented by substituting physiological estrogen 
levels. The degree of cardiac hypertrophy also was measured by normalizing absolute 
heart weight versus tibia length. The ovariectomy of SHR females had showed a trend 
to increase cardiac hypertrophy which was attenuated by estrogen treatment. These 
observations of estrogen efficacy, morphological changes and degree of cardiac 
hypertrophy in female SHR animals, was in agreement with the data reported 
previously (Jazbutyte, Arias-Loza et al. 2008; Pelzer, Jazbutyte et al. 2005) 
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After glucose transporters, hexokinase activity have been implicated as the rate 
limiting step in myocardial 18FDG uptake (Hariharan, Bray et al. 1995; Ratib, Phelps
et al. 1982; Young, Russell et al. 1999). Since intracellular glucose must first be 
phosphorylated for further metabolism, hexokinase is implicated as a critical step for 
control of glucose utilization. Hexokinase activity had showed a significant increase
by E2 treatment that was reduced in ovariectomized SHR cardiac muscle confirms
ability of estrogen treatment increasing the glucose utilization and metabolism in SHR 
animals. 
Microarray analysis in SHR heart showed that ei4Ebp1 and Frap1 genes which are 
involved in mTOR signaling pathway were up-regulated in E2 treated group. These 
two genes are regulating the protein synthesis and activated in presence of glucose in 
the heart contributing to cardiac hypertrophy (Sharma, Guthrie et al. 2007). Since 
phosphorylation of Eif4bp1 is important step in protein synthesis, the reduced levels 
of 4Ebp1 in ovariectomized SHR rat hearts were increased E2 treatment. In contrast 
to up-regulation of Eif4Ebp1 gene by E2 treatment from microarray analysis did not 
show similar pattern on its protein expression instead increased levels of its level in 
ovariectomized SHR heart. These findings suggest a possible link between estrogen 
and well established intermediately metabolism involved mTOR signalling pathway 
with respect to cardiac hypertrophy.
7. Conclusion
In the present study, the reduced myocardial FDG uptake in ovariectomized 
spontaneously hypertensive rat is normalized by 17β-estradiol treatment. The 
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increased serum insulin level and myocardial hexokinase activity warranted increased 
myocardial glucose uptake. The present work showing increased glucose uptake in 
response to 17β-estradiol in ovariectomized SHR may provide a novel mechanism to 
explain known function of estradiol in reduction of cardiac hypertrophy in SHR.
Unaltered glucose transporter (GLUT4) expression/localization or IRS-1 and its
phosphorylation suggesting not a rate limiting for changes in myocardial FDG uptake 
that observed in SHR.
8. Clinical Implications
Decreased cardiac glucose uptake directly responsible for diminish of cardiac energy 
production (Abel 2004; Depre, Vanoverschelde et al. 1999). The lack of energy yield 
not only damage the contractile function, also responsible for inefficiency of 
myocardium manage with ischemia/reperfusion stress (Bugger and Abel 2008; 
Russell, Li et al. 2004). Formation of O2 free radicals and flow of calcium are known 
outcome of ischemia-reperfusion which can be amplified by decline in energy 
formation due to reduced glucose utilization (Bugger and Abel 2008; Ferdinandy, 
Schulz et al. 2007). Post-ischemic contractile dysfunction due to impaired glucose 
uptake and oxidation can improve contractile function by the agents that enhance 
(Depre, Vanoverschelde et al. 1999; Ferdinandy, Schulz et al. 2007; Russell, Li et al.
2004). Therapeutic strategies to agument glucose uptake may beneficial for ischemic 
heart (Wang and Lopaschuk 2007). The improved cardiac glucose metabolism by 
17β-estradiol treatment contributes to its cardio-protective effects.
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10. Abbreviations
ADP Adenine Diphosphate
ANT Adenine Nuclear Transition pore complex
ATP Adenine Triphosphate
cDNA Complementary DNA
CVD Cardio-Vascular Disease
CHF Congestive Heart Failure
DCM Dilated CardioMyopathy
DNA DeoxyriboNucleic Acid
E2 17β-estradiol
ER Estrogen Receptor
ER-α Estrogen Receptor alpha
ER-β Estrogen Receptor beta
ERT Estrogen Replacement Therapy
FDG F(18)-Deoxyglucose
GLUT Glucose Transporter
GAPDH Glycerine aldehyde phosphate dehydrogenase
HK Hexokinase
IR Insulin Receptor
IRS Insulin Receptor Substrate
LVH Left Ventricle Hypertrophy
mRNA messenger RiboNucleic Acid
OGTT Oral Glucose Tolerance Test
PAGE Polyacrylamide gelelektrophoresis
PET Positron Emission Tomography
PI3K PhosphoInositide 3‘-Kinase
PKB Protein Kinase B
PKC Protein Kinase C
PPAR Peroxisome Proliferator Activated Receptor 
RNA Ribonucleic acid
SDS Sodiumdodecylsulfate
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